The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Anti-inflammatory peptides also known as antiflammins inhibit inflammation of a mammal\'s skin, lacerations of the musculature, mucous membranes, or injury into the air spaces of the lungs. Anti-inflammatory peptides act by hindering synthesis of platelet-activating factor, neutrophil aggregation and chemotaxis, and intradermal inflammatory reactions. Anti-Inflammatory peptides are used to treat diseases such as psoriasis, multiple sclerosis, inflammatory bowel disease and other autoimmune diseases.
Due to the COVID-19 pandemic, the global Anti-Inflammatory Peptides market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Anti-Inflammatory Peptides market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Anti-Inflammatory Peptides landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
North America has dominated the entire market in 2014, as it has presence of technologically updated systems, strong research & development, and high patient awareness levels in this region. Latin America is also expected to grow at a healthy rate as a result of increase in both private and public associations, causing an increase in the investment, thereby boosting the demand for the anti-inflammatory peptides. However, the Asia Pacific region is expected to witness lucrative growth during the forecast period owing to the rapidly improving healthcare infrastructure in the growing economies of India and China. Growing patient awareness levels among the population of this region coupled with high unmet needs of the patients is expected to further drive this region.
This report focuses on Anti-Inflammatory Peptides volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Anti-Inflammatory Peptides market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Anti-Inflammatory Peptides Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
- Cardiovascular Diseases
- Gastrointestinal Diseases
- Dermatological Diseases
- Neurological Diseases
- Otorhino Diseases & Ophthalmological
- Respiratory Diseases & Pulmonary
- Renal Diseases
- Rheumatological & Autoimmune Diseases
- Transplantation
Segment by Application
- Hospital Use
- Clinic Use
- Household
- Other
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina, Colombia)
By Company
- Mylan Pharmaceuticals
- Novartis Ag
- Rogne Bioscience
- Merck Serono
- F4 Pharma
- Araim Pharmaceuticals, Inc.
- Digna Biotech
- Abbvie Corporation
Index
1 Anti-Inflammatory Peptides Market Overview
1.1 Product Overview and Scope of Anti-Inflammatory Peptides
1.2 Anti-Inflammatory Peptides Segment by Type
1.2.1 Global Anti-Inflammatory Peptides Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Cardiovascular Diseases
1.2.3 Gastrointestinal Diseases
1.2.4 Dermatological Diseases
1.2.5 Neurological Diseases
1.2.6 Otorhino Diseases & Ophthalmological
1.2.7 Respiratory Diseases & Pulmonary
1.2.8 Renal Diseases
1.2.9 Rheumatological & Autoimmune Diseases
1.2.10 Transplantation
1.3 Anti-Inflammatory Peptides Segment by Application
1.3.1 Global Anti-Inflammatory Peptides Sales Comparison by Application: (2022-2028)
1.3.2 Hospital Use
1.3.3 Clinic Use
1.3.4 Household
1.3.5 Other
1.4 Global Anti-Inflammatory Peptides Market Size Estimates and Forecasts
1.4.1 Global Anti-Inflammatory Peptides Revenue 2017-2028
1.4.2 Global Anti-Inflammatory Peptides Sales 2017-2028
1.4.3 Anti-Inflammatory Peptides Market Size by Region: 2017 Versus 2021 Versus 2028
2 Anti-Inflammatory Peptides Market Competition by Manufacturers
2.1 Global Anti-Inflammatory Peptides Sales Market Share by Manufacturers (2017-2022)
2.2 Global Anti-Inflammatory Peptides Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Anti-Inflammatory Peptides Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Anti-Inflammatory Peptides Manufacturing Sites, Area Served, Product Type
2.5 Anti-Inflammatory Peptides Market Competitive Situation and Trends
2.5.1 Anti-Inflammatory Peptides Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Anti-Inflammatory Peptides Players Market Share by Revenue
2.5.3 Global Anti-Inflammatory Peptides Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-Inflammatory Peptides Retrospective Market Scenario by Region
3.1 Global Anti-Inflammatory Peptides Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Anti-Inflammatory Peptides Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Anti-Inflammatory Peptides Market Facts & Figures by Country
3.3.1 North America Anti-Inflammatory Peptides Sales by Country
3.3.2 North America Anti-Inflammatory Peptides Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Anti-Inflammatory Peptides Market Facts & Figures by Country
3.4.1 Europe Anti-Inflammatory Peptides Sales by Country
3.4.2 Europe Anti-Inflammatory Peptides Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Anti-Inflammatory Peptides Market Facts & Figures by Region
3.5.1 Asia Pacific Anti-Inflammatory Peptides Sales by Region
3.5.2 Asia Pacific Anti-Inflammatory Peptides Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Anti-Inflammatory Peptides Market Facts & Figures by Country
3.6.1 Latin America Anti-Inflammatory Peptides Sales by Country
3.6.2 Latin America Anti-Inflammatory Peptides Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Anti-Inflammatory Peptides Market Facts & Figures by Country
3.7.1 Middle East and Africa Anti-Inflammatory Peptides Sales by Country
3.7.2 Middle East and Africa Anti-Inflammatory Peptides Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Anti-Inflammatory Peptides Historic Market Analysis by Type
4.1 Global Anti-Inflammatory Peptides Sales Market Share by Type (2017-2022)
4.2 Global Anti-Inflammatory Peptides Revenue Market Share by Type (2017-2022)
4.3 Global Anti-Inflammatory Peptides Price by Type (2017-2022)
5 Global Anti-Inflammatory Peptides Historic Market Analysis by Application
5.1 Global Anti-Inflammatory Peptides Sales Market Share by Application (2017-2022)
5.2 Global Anti-Inflammatory Peptides Revenue Market Share by Application (2017-2022)
5.3 Global Anti-Inflammatory Peptides Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Mylan Pharmaceuticals
6.1.1 Mylan Pharmaceuticals Corporation Information
6.1.2 Mylan Pharmaceuticals Description and Business Overview
6.1.3 Mylan Pharmaceuticals Anti-Inflammatory Peptides Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Mylan Pharmaceuticals Anti-Inflammatory Peptides Product Portfolio
6.1.5 Mylan Pharmaceuticals Recent Developments/Updates
6.2 Novartis AG
6.2.1 Novartis AG Corporation Information
6.2.2 Novartis AG Description and Business Overview
6.2.3 Novartis AG Anti-Inflammatory Peptides Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Novartis AG Anti-Inflammatory Peptides Product Portfolio
6.2.5 Novartis AG Recent Developments/Updates
6.3 Rogne Bioscience
6.3.1 Rogne Bioscience Corporation Information
6.3.2 Rogne Bioscience Description and Business Overview
6.3.3 Rogne Bioscience Anti-Inflammatory Peptides Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Rogne Bioscience Anti-Inflammatory Peptides Product Portfolio
6.3.5 Rogne Bioscience Recent Developments/Updates
6.4 Merck Serono
6.4.1 Merck Serono Corporation Information
6.4.2 Merck Serono Description and Business Overview
6.4.3 Merck Serono Anti-Inflammatory Peptides Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Merck Serono Anti-Inflammatory Peptides Product Portfolio
6.4.5 Merck Serono Recent Developments/Updates
6.5 F4 Pharma
6.5.1 F4 Pharma Corporation Information
6.5.2 F4 Pharma Description and Business Overview
6.5.3 F4 Pharma Anti-Inflammatory Peptides Sales, Revenue and Gross Margin (2017-2022)
6.5.4 F4 Pharma Anti-Inflammatory Peptides Product Portfolio
6.5.5 F4 Pharma Recent Developments/Updates
6.6 Araim Pharmaceuticals, Inc.
6.6.1 Araim Pharmaceuticals, Inc. Corporation Information
6.6.2 Araim Pharmaceuticals, Inc. Description and Business Overview
6.6.3 Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Product Portfolio
6.6.5 Araim Pharmaceuticals, Inc. Recent Developments/Updates
6.7 Digna Biotech
6.6.1 Digna Biotech Corporation Information
6.6.2 Digna Biotech Description and Business Overview
6.6.3 Digna Biotech Anti-Inflammatory Peptides Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Digna Biotech Anti-Inflammatory Peptides Product Portfolio
6.7.5 Digna Biotech Recent Developments/Updates
6.8 Abbvie Corporation
6.8.1 Abbvie Corporation Corporation Information
6.8.2 Abbvie Corporation Description and Business Overview
6.8.3 Abbvie Corporation Anti-Inflammatory Peptides Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Abbvie Corporation Anti-Inflammatory Peptides Product Portfolio
6.8.5 Abbvie Corporation Recent Developments/Updates
7 Anti-Inflammatory Peptides Manufacturing Cost Analysis
7.1 Anti-Inflammatory Peptides Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Anti-Inflammatory Peptides
7.4 Anti-Inflammatory Peptides Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Anti-Inflammatory Peptides Distributors List
8.3 Anti-Inflammatory Peptides Customers
9 Anti-Inflammatory Peptides Market Dynamics
9.1 Anti-Inflammatory Peptides Industry Trends
9.2 Anti-Inflammatory Peptides Market Drivers
9.3 Anti-Inflammatory Peptides Market Challenges
9.4 Anti-Inflammatory Peptides Market Restraints
10 Global Market Forecast
10.1 Anti-Inflammatory Peptides Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Anti-Inflammatory Peptides by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Anti-Inflammatory Peptides by Type (2023-2028)
10.2 Anti-Inflammatory Peptides Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Anti-Inflammatory Peptides by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Anti-Inflammatory Peptides by Application (2023-2028)
10.3 Anti-Inflammatory Peptides Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Anti-Inflammatory Peptides by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Anti-Inflammatory Peptides by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
List of Tables
Table 1. Global Anti-Inflammatory Peptides Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Anti-Inflammatory Peptides Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Anti-Inflammatory Peptides Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Anti-Inflammatory Peptides Market Competitive Situation by Manufacturers in 2021
Table 5. Global Anti-Inflammatory Peptides Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Anti-Inflammatory Peptides Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Anti-Inflammatory Peptides Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Anti-Inflammatory Peptides Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Anti-Inflammatory Peptides Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Anti-Inflammatory Peptides Manufacturing Sites and Area Served
Table 11. Manufacturers Anti-Inflammatory Peptides Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Anti-Inflammatory Peptides by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Inflammatory Peptides as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Anti-Inflammatory Peptides Sales by Region (2017-2022) & (K Units)
Table 16. Global Anti-Inflammatory Peptides Sales Market Share by Region (2017-2022)
Table 17. Global Anti-Inflammatory Peptides Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Anti-Inflammatory Peptides Revenue Market Share by Region (2017-2022)
Table 19. North America Anti-Inflammatory Peptides Sales by Country (2017-2022) & (K Units)
Table 20. North America Anti-Inflammatory Peptides Sales Market Share by Country (2017-2022)
Table 21. North America Anti-Inflammatory Peptides Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Anti-Inflammatory Peptides Revenue Market Share by Country (2017-2022)
Table 23. Europe Anti-Inflammatory Peptides Sales by Country (2017-2022) & (K Units)
Table 24. Europe Anti-Inflammatory Peptides Sales Market Share by Country (2017-2022)
Table 25. Europe Anti-Inflammatory Peptides Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Anti-Inflammatory Peptides Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Anti-Inflammatory Peptides Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Anti-Inflammatory Peptides Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Anti-Inflammatory Peptides Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Anti-Inflammatory Peptides Revenue Market Share by Region (2017-2022)
Table 31. Latin America Anti-Inflammatory Peptides Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Anti-Inflammatory Peptides Sales Market Share by Country (2017-2022)
Table 33. Latin America Anti-Inflammatory Peptides Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Anti-Inflammatory Peptides Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Anti-Inflammatory Peptides Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Anti-Inflammatory Peptides Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Anti-Inflammatory Peptides Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Anti-Inflammatory Peptides Revenue Market Share by Country (2017-2022)
Table 39. Global Anti-Inflammatory Peptides Sales by Type (2017-2022) & (K Units)
Table 40. Global Anti-Inflammatory Peptides Sales Market Share by Type (2017-2022)
Table 41. Global Anti-Inflammatory Peptides Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Anti-Inflammatory Peptides Revenue Share by Type (2017-2022)
Table 43. Global Anti-Inflammatory Peptides Price by Type (2017-2022) & (USD/Unit)
Table 44. Global Anti-Inflammatory Peptides Sales (K Units) by Application (2017-2022)
Table 45. Global Anti-Inflammatory Peptides Sales Market Share by Application (2017-2022)
Table 46. Global Anti-Inflammatory Peptides Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Anti-Inflammatory Peptides Revenue Share by Application (2017-2022)
Table 48. Global Anti-Inflammatory Peptides Price by Application (2017-2022) & (USD/Unit)
Table 49. Mylan Pharmaceuticals Corporation Information
Table 50. Mylan Pharmaceuticals Description and Business Overview
Table 51. Mylan Pharmaceuticals Anti-Inflammatory Peptides Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. Mylan Pharmaceuticals Anti-Inflammatory Peptides Product
Table 53. Mylan Pharmaceuticals Recent Developments/Updates
Table 54. Novartis AG Corporation Information
Table 55. Novartis AG Description and Business Overview
Table 56. Novartis AG Anti-Inflammatory Peptides Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 57. Novartis AG Anti-Inflammatory Peptides Product
Table 58. Novartis AG Recent Developments/Updates
Table 59. Rogne Bioscience Corporation Information
Table 60. Rogne Bioscience Description and Business Overview
Table 61. Rogne Bioscience Anti-Inflammatory Peptides Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 62. Rogne Bioscience Anti-Inflammatory Peptides Product
Table 63. Rogne Bioscience Recent Developments/Updates
Table 64. Merck Serono Corporation Information
Table 65. Merck Serono Description and Business Overview
Table 66. Merck Serono Anti-Inflammatory Peptides Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 67. Merck Serono Anti-Inflammatory Peptides Product
Table 68. Merck Serono Recent Developments/Updates
Table 69. F4 Pharma Corporation Information
Table 70. F4 Pharma Description and Business Overview
Table 71. F4 Pharma Anti-Inflammatory Peptides Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 72. F4 Pharma Anti-Inflammatory Peptides Product
Table 73. F4 Pharma Recent Developments/Updates
Table 74. Araim Pharmaceuticals, Inc. Corporation Information
Table 75. Araim Pharmaceuticals, Inc. Description and Business Overview
Table 76. Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Product
Table 78. Araim Pharmaceuticals, Inc. Recent Developments/Updates
Table 79. Digna Biotech Corporation Information
Table 80. Digna Biotech Description and Business Overview
Table 81. Digna Biotech Anti-Inflammatory Peptides Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. Digna Biotech Anti-Inflammatory Peptides Product
Table 83. Digna Biotech Recent Developments/Updates
Table 84. Abbvie Corporation Corporation Information
Table 85. Abbvie Corporation Description and Business Overview
Table 86. Abbvie Corporation Anti-Inflammatory Peptides Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Abbvie Corporation Anti-Inflammatory Peptides Product
Table 88. Abbvie Corporation Recent Developments/Updates
Table 89. Production Base and Market Concentration Rate of Raw Material
Table 90. Key Suppliers of Raw Materials
Table 91. Anti-Inflammatory Peptides Distributors List
Table 92. Anti-Inflammatory Peptides Customers List
Table 93. Anti-Inflammatory Peptides Market Trends
Table 94. Anti-Inflammatory Peptides Market Drivers
Table 95. Anti-Inflammatory Peptides Market Challenges
Table 96. Anti-Inflammatory Peptides Market Restraints
Table 97. Global Anti-Inflammatory Peptides Sales Forecast by Type (2023-2028) & (K Units)
Table 98. Global Anti-Inflammatory Peptides Sales Market Share Forecast by Type (2023-2028)
Table 99. Global Anti-Inflammatory Peptides Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 100. Global Anti-Inflammatory Peptides Revenue Market Share Forecast by Type (2023-2028)
Table 101. Global Anti-Inflammatory Peptides Sales Forecast by Application (2023-2028) & (K Units)
Table 102. Global Anti-Inflammatory Peptides Sales Market Share Forecast by Application (2023-2028)
Table 103. Global Anti-Inflammatory Peptides Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 104. Global Anti-Inflammatory Peptides Revenue Market Share Forecast by Application (2023-2028)
Table 105. Global Anti-Inflammatory Peptides Sales Forecast by Region (2023-2028) & (K Units)
Table 106. Global Anti-Inflammatory Peptides Sales Market Share Forecast by Region (2023-2028)
Table 107. Global Anti-Inflammatory Peptides Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 108. Global Anti-Inflammatory Peptides Revenue Market Share Forecast by Region (2023-2028)
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-Inflammatory Peptides
Figure 2. Global Anti-Inflammatory Peptides Market Share by Type in 2021 & 2028
Figure 3. Cardiovascular Diseases Product Picture
Figure 4. Gastrointestinal Diseases Product Picture
Figure 5. Dermatological Diseases Product Picture
Figure 6. Neurological Diseases Product Picture
Figure 7. Otorhino Diseases & Ophthalmological Product Picture
Figure 8. Respiratory Diseases & Pulmonary Product Picture
Figure 9. Renal Diseases Product Picture
Figure 10. Rheumatological & Autoimmune Diseases Product Picture
Figure 11. Transplantation Product Picture
Figure 12. Global Anti-Inflammatory Peptides Market Share by Application in 2021 & 2028
Figure 13. Hospital Use
Figure 14. Clinic Use
Figure 15. Household
Figure 16. Other
Figure 17. Global Anti-Inflammatory Peptides Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 18. Global Anti-Inflammatory Peptides Market Size (2017-2028) & (US$ Million)
Figure 19. Global Anti-Inflammatory Peptides Sales (2017-2028) & (K Units)
Figure 20. Anti-Inflammatory Peptides Sales Share by Manufacturers in 2021
Figure 21. Global Anti-Inflammatory Peptides Revenue Share by Manufacturers in 2021
Figure 22. The Global 5 and 10 Largest Anti-Inflammatory Peptides Players: Market Share by Revenue in 2021
Figure 23. Anti-Inflammatory Peptides Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 24. Global Anti-Inflammatory Peptides Sales Market Share by Region (2017-2022)
Figure 25. Global Anti-Inflammatory Peptides Sales Market Share by Region in 2021
Figure 26. Global Anti-Inflammatory Peptides Revenue Market Share by Region (2017-2022)
Figure 27. Global Anti-Inflammatory Peptides Revenue Market Share by Region in 2021
Figure 28. U.S. Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Canada Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Germany Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. France Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. U.K. Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Italy Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Russia Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. China Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Japan Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. South Korea Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. India Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Australia Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Taiwan Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Indonesia Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Thailand Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Malaysia Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Philippines Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Vietnam Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. Mexico Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. Brazil Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 48. Argentina Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 49. Turkey Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 50. Saudi Arabia Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 51. U.A.E Anti-Inflammatory Peptides Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 52. Sales Market Share of Anti-Inflammatory Peptides by Type (2017-2022)
Figure 53. Manufacturing Cost Structure of Anti-Inflammatory Peptides
Figure 54. Manufacturing Process Analysis of Anti-Inflammatory Peptides
Figure 55. Anti-Inflammatory Peptides Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
